Overview

Irofulven in Treating Children With Recurrent or Refractory Solid Tumors

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase I trial to study the effectiveness of irofulven in treating children with recurrent or refractory solid tumors. Drugs used in chemotherapy use different ways to stop tumor cells so they stop growing or die.
Phase:
Phase 1
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Irofulven